Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07682831

Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies

The goal of this study is to investigate the ability of a machine learning model to evaluate two-photon fluorescence microscopy images of dermatologic biopsies at point of care.

The main question it aims to answer is:

• How well do two-photon fluorescence images of biopsies taken in a clinic and evaluated by a machine learning model agree with conventional histology?

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rochester Dermatologic Surgery

Victor, New York, 14654, United States

Location contact

Sherrif Ibrahim, M.D.-Ph.D.

CONTACT

[email protected]

585-222-1400

About this study

This study will image biopsy specimens at point of care using two-photon fluorescence microscopy (TPFM) and then assess how well the images predict the eventual clinical diagnosis using a machine learning model. Because two-photon images can be acquired from small biopsy specimens within minutes of excision, they could potentially be used to immediately diagnose patients, but the accuracy of TPFM for various skin conditions is unknown.

Individual biopsy specimens in a dermatology clinic will be imaged using TPFM shortly after biopsy procedures. Immediately following imaging, a machine learning model will evaluate the TPFM images then compute a confidence score for a diagnosis of basal cell carcinoma (BCC), squamous cell carcinoma, and non-cancer. The relative confidence in each diagnosis will be compared, and if sufficient confidence is achieved, the model will render a diagnosis or else flag the specimen as indeterminate for manual pathologist review. This workflow will evaluate the use of ML + TPFM to perform point of care diagnosis of skin lesions.

Following TPFM imaging, the specimen will be submitted for histological processing, which will guide actual patient treatment. Following conclusion of patient treatment, the resulting histology slides will be scanned for comparison and the final patient diagnosis recorded. Images of the histology slides will be read by a pathologist to establish a gold-standard diagnosis. The official diagnosis and the diagnosis from the collaborating pathologist will be compared.

Patient treatment will still be decided by conventional histopathology. TPFM will not be used to change treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Punch, excisional or shave biopsy specimen

Exclusion criteria

  • Biopsy indication includes melanoma or dysplastic/atypical nevus
  • Excision thickness of less than 1 mm
  • Excision longest dimension less than 2 mm
  • Excision performed as multiple pieces in a single specimen container

Treatment and study plan

Two photon microscopy imaging

Device

Ex vivo tissues will be imaged with two-photon microscopy and analyzed with machine learning for diagnosis

Primary outcomes

  1. Sensitivity of Machine Learning Analysis of Two Photon Fluorescence Microscopy Images At Point of Care

    Time frame: During or immediately following patient biopsy (same day)

    A machine learning model will evaluate TPFM images of patient biopsies at point of care. Sensitivity will be calculated for the machine learning model using two photon fluorescence microscopy images. Sensitivity is defined as the number of true positive diagnoses divided by the sum of true positive and false negative diagnoses among biopsy specimens for which the machine learning model provides a definitive diagnosis. The patient's ultimate clinical diagnosis will serve as the reference standard.

  2. Specificity of Machine Learning Analysis of Two Photon Fluorescence Microscopy Images At Point of Care

    Time frame: During or immediately following patient biopsy (same day)

    A machine learning model will evaluate TPFM images of patient biopsies at point of care. Specificity will be calculated for the machine learning model using two photon fluorescence microscopy images. Specificity is defined as the number of true negative diagnoses divided by the sum of true negative and false positive diagnoses among biopsy specimens for which the machine learning model provides a definitive diagnosis. The patient's ultimate clinical diagnosis will serve as the reference standard.

Secondary outcomes

  1. Proportion of Discordant Diagnoses Attributable to Machine Learning Model Interpretation Errors

    Time frame: After completion of patient diagnosis (typically 1-2 weeks after procedure)

    For biopsy specimens with discordant diagnoses between the machine learning model and the patient's ultimate clinical diagnosis, a dermatopathologist will review each case and classify the source of disagreement as machine learning model interpretation error, image quality limitation, or image coregistration error. The proportion of discordant diagnoses attributable to each source of disagreement will be reported.

  2. Proportion of Biopsy Specimens With a Definitive Machine Learning Diagnosis

    Time frame: During or immediately following patient biopsy (same day)

    The proportion of biopsy specimens for which the machine learning model provides a definitive diagnosis based on two photon fluorescence microscopy images will be calculated as the number of specimens receiving a definitive diagnosis divided by the total number of specimens evaluated.

Study contacts

Contact information is provided by the study sponsor or research team.

Michael Giacomelli, Ph.D

CONTACT

[email protected]

5852766260

Sponsors and collaborators

Lead sponsor

University of Rochester

Other

Collaborators

  • National Cancer Institute (NCI)
  • Rochester Dermatologic Surgery

Registry information

Official study title

Machine Learning Analysis of Expanded Two-photon Imaging of Skin Biopsy Specimens

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 6, 2026
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.